By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Novartis had already given up developing iscalimab for liver transplant patients in 2022 after a phase 2 trial found the drug had a “less favorable risk-benefit profile” than tacrolimus ...

DAVENPORT & Co LLC reduced its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 3.3% in the fourth quarter, ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...